In vivo imaging of NF-κB activity in mice with PEL. (A) NOD/SCID mice were challenged with 10 × 106 BC3/NFκB-luc traceable cells and subsequently received injections of vehicle (left) or 5 mg/kg Bay 11-7082 (right) on days 3, 5, and 7 after tumor challenge. Mice were imaged on the days indicated after injection with luciferin. ROI chosen for data acquisition is shown by the green oval over each mouse. (B) Luciferase activity was measured in the BC3/NFκB-luc cell line after treatment with Bay 11-7082 in vitro showing a reliable dose- and time-dependent response to NF-κB inhibition. Error bars represent SD. (C) Bioluminescence was quantitated and reported as relative bioluminescence units (BLU) at different time intervals for each mouse studied. All but 2 mice showed luminescence above background levels at day 3 (before drug injection); mouse 2 in the vehicle group did not develop detectable tumor until approximately day 33 of the experiment and is, therefore, not shown in panel A, and mouse 2 in the Bay 11 20-mg/kg dose group has not developed visible tumor to date. Treatment with Bay 11-7082 resulted in decreased bioluminescence by 24 hours, indicating decreased NF-κB activity. The luminescence remained low in the mice treated with Bay 11-7082 (squares), whereas it increased progressively in the mice treated with vehicle alone (triangles). Mice for which the line was interrupted before the last point in time shown represent those that developed ascites and were humanely killed.
